Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

DTIL

Precision Biosciences Inc

Feb 13 • 04:00PM ET

3.89

-0.07 -1.77 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT SGMO VRTX BLUE ALLO CLLS ADAP IBRX

| Held by: VTI VXF IWC XDNA DFAS DFAC

Index	-	P/E	-	EPS (ttm)	-8.40	Insider Own	21.05%	Shs Outstand	24.07M	Perf Week	2.37%
Market Cap	93.64M	Forward P/E	-	EPS next Y	-2.85	Insider Trans	-1.23%	Shs Float	19.00M	Perf Month	-5.81%
Enterprise Value	77.90M	PEG	-	EPS next Q	-0.54	Inst Own	48.19%	Short Float	7.26%	Perf Quarter	-35.17%
Income	-83.60M	P/S	133.77	EPS this Y	-689.90%	Inst Trans	15.09%	Short Ratio	6.04	Perf Half Y	-18.45%
Sales	0.70M	P/B	2.83	EPS next Y	53.55%	ROA	-67.76%	Short Interest	1.38M	Perf YTD	-6.49%
Book/sh	1.38	P/C	2.09	EPS next 5Y	-	ROE	-205.16%	52W High	8.82 -55.90%	Perf Year	-23.12%
Cash/sh	1.86	P/FCF	-	EPS past 3/5Y	- -	ROIC	-188.70%	52W Low	3.53 10.20%	Perf 3Y	-88.72%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-15.91% 25.30%	Gross Margin	-305.73%	Volatility	7.22% 7.23%	Perf 5Y	-99.01%
Dividend TTM	-	EV/Sales	111.29	EPS Y/Y TTM	-10347.56%	Oper. Margin	-12822.64%	ATR (14)	0.28	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.45	Sales Y/Y TTM	-99.07%	Profit Margin	-11977.36%	RSI (14)	45.34	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.45	EPS Q/Q	18.27%	SMA20	-1.90%	Beta	1.29	Target Price	32.50
Payout	0.00%	Debt/Eq	1.75	Sales Q/Q	-97.74%	SMA50	-8.81%	Rel Volume	0.39	Prev Close	3.96
Employees	108	LT Debt/Eq	1.66	Earnings	Nov 03 BMO	SMA200	-22.03%	Avg Volume	228.32K	Price	3.89
IPO	Mar 28, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-37.31% -99.76%	Trades		Volume	89,727	Change	-1.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-10-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$34
Apr-30-24	Initiated	Guggenheim	Buy	$19
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$7
Jun-09-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-27-20	Resumed	BTIG Research	Buy	$16
Apr-03-20	Downgrade	Goldman	Buy → Neutral	$24 → $7
Mar-05-20	Initiated	Stifel	Buy	$21
Feb-25-20	Initiated	William Blair	Outperform
Aug-09-19	Initiated	BTIG Research	Buy	$22
Jul-16-19	Initiated	H.C. Wainwright	Buy	$21
Apr-22-19	Initiated	JP Morgan	Overweight
Apr-22-19	Initiated	Jefferies	Buy
Apr-22-19	Initiated	Goldman	Buy
Apr-22-19	Initiated	Barclays	Overweight

Show Previous Ratings

Jan-12-26 07:01AM	Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy (Business Wire)
Dec-23-25 07:00AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-19-25 07:01AM	Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 (Business Wire) -7.66%
Nov-10-25 06:12PM	Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants (Business Wire)
05:21PM	Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts (Business Wire)
07:10AM	Loading…
Nov-03-25 07:10AM	Precision BioSciences: Q3 Earnings Snapshot (Associated Press Finance) -9.80%
07:01AM	Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Oct-31-25 07:01AM	Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025 (Business Wire) -5.23%
Oct-16-25 08:05AM	Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last? (Zacks)
Oct-14-25 07:01AM	Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2025 (Business Wire) +5.22%
Oct-09-25 07:01AM	Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases (Business Wire)
Oct-07-25 07:01AM	Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial (Business Wire)
Sep-30-25 07:01AM	Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society (Business Wire) +8.45%
Sep-25-25 06:30AM	Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? (Zacks)
Sep-12-25 07:01AM	Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium (Business Wire) -7.80%
07:01AM	Loading…
Sep-08-25 07:01AM	Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status (Business Wire)
Aug-07-25 09:25AM	Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:24AM	Precision BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
07:01AM	Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Aug-06-25 05:45PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:01AM	Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B (Business Wire)
Aug-05-25 06:20PM	Qiagen (QGEN) Matches Q2 Earnings Estimates (Zacks)
Aug-04-25 07:01AM	Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025 (Business Wire)
Jul-23-25 07:01AM	Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (Business Wire)
Jul-16-25 07:01AM	Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic (Business Wire)
Jun-25-25 07:01AM	Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (Business Wire) -7.22%
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-15-25 08:15AM	Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -8.08%
07:11AM	Precision BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
07:01AM	Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
05:45PM	Loading…
May-14-25 05:45PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:30PM	Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-12-25 05:30PM	Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:01AM	Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 (Business Wire)
May-07-25 07:01AM	Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) (Business Wire)
May-06-25 05:15PM	Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -9.09%
08:00AM	iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings (Business Wire)
May-05-25 04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-01-25 07:01AM	Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
Apr-29-25 07:00AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-16-25 08:52AM	DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up (Zacks) -9.24%
Apr-15-25 07:01AM	Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B (Business Wire) +23.77%
Apr-10-25 11:50AM	TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why (Zacks) -7.03%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -5.87%
07:01AM	Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-26-25 08:10AM	Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -11.00%
07:09AM	Precision BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-21-25 07:01AM	Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 (Business Wire)
Mar-20-25 07:01AM	Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 (Business Wire) +6.99%
Mar-19-25 06:25PM	Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire)
Mar-17-25 07:01AM	Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B (Business Wire)
Feb-24-25 07:01AM	Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire) -5.06%
Feb-20-25 07:47AM	Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV (Clinical Trials Arena)
Feb-19-25 02:27PM	Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate (Benzinga) +9.71%
07:01AM	Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial (Business Wire)
Jan-29-25 07:01AM	Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs (Business Wire)
Jan-09-25 10:01AM	Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
08:00AM	iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
Dec-19-24 05:42AM	Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial (Clinical Trials Arena) +11.38%
Dec-18-24 07:01AM	Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B (Business Wire) -9.83%
Nov-21-24 07:01AM	Precision BioSciences to Participate in Upcoming November Investor Conferences (Business Wire) -9.47%
Nov-15-24 07:00AM	Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B (Business Wire)
Nov-04-24 08:15AM	Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.09%
07:13AM	Precision BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
07:01AM	Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-01-24 07:43AM	Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? (Zacks) +5.37%
Oct-29-24 07:01AM	Precision BioSciences to Report Third Quarter Results on November 4, 2024 (Business Wire)
Oct-28-24 07:01AM	Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 (Business Wire)
Oct-24-24 04:15PM	Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress (Business Wire)
08:47AM	Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B (Business Wire)
Oct-21-24 07:01AM	Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences (Business Wire)
Oct-16-24 07:01AM	Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress (Business Wire)
Oct-03-24 07:01AM	Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (Business Wire)
Sep-30-24 07:01AM	Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B (Business Wire)
Sep-20-24 07:01AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-24 09:55AM	Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet (Zacks)
Sep-12-24 07:15AM	Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution (Business Wire)
Sep-11-24 08:50AM	Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock (Zacks)
Sep-04-24 07:01AM	Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference (Business Wire)
Sep-03-24 07:01AM	Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal (Business Wire)
Aug-28-24 09:55AM	Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade (Zacks)
Aug-12-24 04:32AM	FDA grants IND clearance for TG Therapeutics trial of multiple sclerosis treatment (Clinical Trials Arena)
Aug-09-24 07:01AM	Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis (Business Wire)
Aug-01-24 08:25AM	Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates (Zacks)
07:22AM	Precision BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
07:15AM	Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-31-24 07:01AM	Precision BioSciences to Participate in Upcoming August Investor Conferences (Business Wire)
Jul-29-24 04:15PM	Precision BioSciences to Report Second Quarter Results on August 1, 2024 (Business Wire)
Jul-08-24 07:01AM	Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit (Business Wire)
Jul-01-24 07:01AM	Precision BioSciences Announces its Addition to the Russell Microcap Index (Business Wire)
Jun-27-24 07:01AM	Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025 (Business Wire)
Jun-20-24 07:00AM	Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness (Business Wire)
Jun-05-24 07:01AM	Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress (Business Wire)
May-30-24 07:00AM	Precision BioSciences to Participate in Upcoming June Investor Conferences (Business Wire)
May-29-24 09:55AM	Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect? (Zacks)
May-17-24 07:00AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-13-24 11:53AM	DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +8.08%
07:22AM	Precision BioSciences Reports Profit From Cont. Ops. In Q1 (RTT News)

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Amoroso Michael	President and CEO	Jan 22 '26	Sale	4.17	34,799	145,112	196,154	Jan 22 06:49 PM
Scimeca Dario	General Counsel and Secretary	Jan 20 '26	Option Exercise	0.00	25,311	0	53,569	Jan 22 06:48 PM
Scimeca Dario	General Counsel and Secretary	Jan 21 '26	Sale	4.03	8,854	35,682	44,715	Jan 22 06:48 PM
Kelly John Alexander	Chief Financial Officer	Jan 21 '26	Sale	4.03	15,213	61,308	106,448	Jan 22 06:48 PM
SMITH J. JEFFERSON	Chief Research Officer	Jan 21 '26	Sale	4.03	10,200	41,106	110,184	Jan 22 06:48 PM
Amoroso Michael	Officer	Jan 22 '26	Proposed Sale	4.17	34,799	145,202		Jan 22 03:19 PM
Scimeca Dario	Officer	Jan 21 '26	Proposed Sale	4.03	8,854	35,653		Jan 21 04:19 PM
SMITH J. JEFFERSON	Officer	Jan 21 '26	Proposed Sale	4.03	10,200	41,073		Jan 21 04:14 PM
Kelly John Alexander	Officer	Jan 21 '26	Proposed Sale	4.03	15,213	61,260		Jan 21 04:07 PM
Germano Geno J	Director	Dec 16 '25	Buy	4.72	3,000	14,160	23,883	Dec 17 07:02 AM
Frankel Stanley	Director	Dec 16 '25	Buy	4.70	2,700	12,690	19,478	Dec 17 07:01 AM
Brown Melinda	Director	Dec 15 '25	Buy	4.97	1,381	6,864	23,346	Dec 17 07:00 AM
Kelly John Alexander	Chief Financial Officer	Nov 02 '25	Option Exercise	0.00	3,605	0	78,601	Nov 04 04:15 PM
Kelly John Alexander	Chief Financial Officer	Nov 03 '25	Sale	6.49	1,303	8,456	77,298	Nov 04 04:15 PM
Scimeca Dario	General Counsel and Secretary	Nov 02 '25	Option Exercise	0.00	1,835	0	28,923	Nov 04 04:15 PM
Scimeca Dario	General Counsel and Secretary	Nov 03 '25	Sale	6.49	665	4,316	28,258	Nov 04 04:15 PM
Amoroso Michael	President and CEO	Nov 02 '25	Option Exercise	0.00	9,444	0	118,984	Nov 04 04:15 PM
Amoroso Michael	President and CEO	Nov 03 '25	Sale	6.49	3,409	22,124	115,575	Nov 04 04:15 PM
Kelly John Alexander	Officer	Nov 03 '25	Proposed Sale	6.49	1,303	8,455		Nov 03 03:16 PM
Amoroso Michael	Officer	Nov 03 '25	Proposed Sale	6.49	3,409	22,121		Nov 03 03:15 PM
Scimeca Dario	Officer	Nov 03 '25	Proposed Sale	6.49	665	4,315		Nov 03 03:07 PM
Frankel Stanley	Director	Sep 26 '25	Buy	4.97	2,700	13,419	16,778	Sep 30 07:00 AM
Brown Melinda	Director	Sep 22 '25	Buy	4.89	1,400	6,846	21,965	Sep 24 07:00 AM
Kelly John Alexander	Chief Financial Officer	Jul 03 '25	Sale	4.26	14,827	63,163	73,485	Jul 08 04:30 PM
Kelly John Alexander	Officer	Jul 03 '25	Proposed Sale	4.26	14,827	63,208		Jul 03 03:25 PM
Brown Melinda	Director	Jun 25 '25	Buy	4.14	1,682	6,963	20,565	Jun 27 06:14 AM
Buehler Kevin	Director	Jun 25 '25	Buy	4.16	5,076	21,116	28,137	Jun 27 06:14 AM
Buehler Kevin	Director	Mar 26 '25	Buy	4.67	4,523	21,122	13,235	Mar 28 07:02 AM
Brown Melinda	Director	Mar 26 '25	Buy	4.75	1,839	8,735	9,057	Mar 28 07:00 AM
Germano Geno J	Director	Mar 25 '25	Buy	5.30	3,250	17,225	11,057	Mar 27 07:00 AM
Amoroso Michael	President and CEO	Mar 24 '25	Sale	5.56	964	5,360	109,540	Mar 25 06:00 PM
Amoroso Michael	Officer	Mar 24 '25	Proposed Sale	5.56	964	5,355		Mar 24 03:13 PM
SMITH J. JEFFERSON	Chief Research Officer	Mar 04 '25	Sale	4.91	154	756	87,805	Mar 05 07:00 PM
Scimeca Dario	General Counsel and Secretary	Mar 04 '25	Sale	4.91	272	1,336	25,000	Mar 05 07:00 PM
List Alan	Officer	Mar 05 '25	Proposed Sale	5.06	333	1,684		Mar 05 03:17 PM
SMITH J. JEFFERSON	Officer	Mar 04 '25	Proposed Sale	4.91	154	756		Mar 04 04:15 PM
Scimeca Dario	Officer	Mar 04 '25	Proposed Sale	4.91	272	1,336		Mar 04 04:13 PM

Open in Screener

RNXT

RenovoRx Inc

Feb 13 • 04:00PM ET

0.9333

+0.0031 0.33 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP ALNY NTLA ARWR EDIT FATE ADVM BLUE CLLS

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	3.54%	Shs Outstand	36.65M	Perf Week	-5.73%
Market Cap	34.21M	Forward P/E	-	EPS next Y	-0.25	Insider Trans	6.92%	Shs Float	35.35M	Perf Month	-11.95%
Enterprise Value	24.41M	PEG	-	EPS next Q	-0.08	Inst Own	19.63%	Short Float	1.58%	Perf Quarter	-6.67%
Income	-11.11M	P/S	36.78	EPS this Y	20.63%	Inst Trans	-2.27%	Short Ratio	1.96	Perf Half Y	-24.73%
Sales	0.93M	P/B	4.23	EPS next Y	20.47%	ROA	-104.58%	Short Interest	0.56M	Perf YTD	11.09%
Book/sh	0.22	P/C	3.41	EPS next 5Y	51.14%	ROE	-146.61%	52W High	1.45 -35.63%	Perf Year	-9.39%
Cash/sh	0.27	P/FCF	-	EPS past 3/5Y	17.62% 2.24%	ROIC	-135.23%	52W Low	0.70 33.21%	Perf 3Y	-76.01%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.83% 7.17%	Perf 5Y	-
Dividend TTM	-	EV/Sales	26.25	EPS Y/Y TTM	37.89%	Oper. Margin	-1252.16%	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.68	Sales Y/Y TTM	-	Profit Margin	-1196.66%	RSI (14)	45.26	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.83	EPS Q/Q	19.78%	SMA20	-4.64%	Beta	1.33	Target Price	6.62
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-2.87%	Rel Volume	0.45	Prev Close	0.93
Employees	10	LT Debt/Eq	0.02	Earnings	Nov 13 AMC	SMA200	-16.02%	Avg Volume	284.96K	Price	0.93
IPO	Aug 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -34.39%	Trades		Volume	127,564	Change	0.33%

Feb-10-26 08:30AM	RenovoRx Establishes RenovoCath Medical Advisory Board (GlobeNewswire)
Feb-05-26 08:30AM	RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer (GlobeNewswire)
Feb-04-26 08:30AM	RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting (GlobeNewswire)
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire) +8.33%
Jan-28-26 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting (GlobeNewswire)
08:30AM	Loading…
Jan-20-26 08:30AM	RenovoRx Expands RenovoCath Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center (GlobeNewswire)
Jan-14-26 08:30AM	RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 (GlobeNewswire)
Jan-08-26 08:30AM	RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 (GlobeNewswire) +13.86%
Dec-11-25 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 (GlobeNewswire)
Dec-08-25 09:00AM	Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 (ACCESSWIRE)
Dec-01-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th (GlobeNewswire) -6.59%
Nov-19-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th (GlobeNewswire) -6.38%
Nov-14-25 12:04AM	RenovoRx Inc (RNXT) Q3 2025 Earnings Call Highlights: Strong Commercial Momentum and Strategic ... (GuruFocus.com) -23.03%
Nov-13-25 05:30PM	RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update (GlobeNewswire)
07:36AM	Loading…
Nov-12-25 07:36AM	RenovoRx Inc (RNXT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) -6.54%
Nov-06-25 08:30AM	RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD (GlobeNewswire) -6.23%
Nov-04-25 08:30AM	RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th (GlobeNewswire) -6.42%
Oct-27-25 08:30AM	RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET (GlobeNewswire)
Oct-17-25 09:50AM	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation (PR Newswire)
Oct-09-25 08:30AM	RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baere, MD, PhD (GlobeNewswire) -7.44%
Sep-25-25 08:30AM	RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites (GlobeNewswire)
Sep-11-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th (GlobeNewswire) +5.98%
Aug-20-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025 (Business Wire) -5.58%
Aug-15-25 03:24AM	RenovoRx Inc (RNXT) Q2 2025 Earnings Call Highlights: Strong Market Demand and Strategic Trials ... (GuruFocus.com) -22.94%
Aug-14-25 05:20PM	RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review (Business Wire)
Aug-06-25 08:30AM	RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath Device with Growing Customer Demand and Key Leadership Hire (GlobeNewswire)
Jul-28-25 08:30AM	RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath Device to Solid Tumors (Business Wire)
Jul-14-25 08:30AM	RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET (Business Wire) +8.95%
11:00PM	Loading…
Jun-05-25 11:00PM	RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results (Insider Monkey)
May-16-25 09:42AM	Q1 2025 RenovoRx Inc Earnings Call (Thomson Reuters StreetEvents) +6.31%
03:15AM	RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ... (GuruFocus.com)
May-15-25 07:30PM	RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.71%
04:05PM	RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-14-25 08:30AM	RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st (Business Wire)
May-06-25 08:30AM	U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP) Therapy Platform (Business Wire)
May-01-25 08:30AM	RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET (Business Wire)
Apr-29-25 08:30AM	Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRxs Ongoing Phase III TIGeR-PaC Clinical Trial (Business Wire)
Apr-16-25 08:30AM	RenovoRx Increases U.S. Production of RenovoCath Devices to Meet Growing Demand from Oncology Community (Business Wire) +14.44%
Apr-04-25 08:30AM	RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th (Business Wire)
Apr-01-25 08:30AM	RenovoRx Reports Initial Revenues from RenovoCath Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (Business Wire)
Mar-28-25 08:00AM	RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting (Business Wire)
Mar-26-25 08:00AM	RenovoRx Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting (Business Wire)
Mar-20-25 08:00AM	RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET (Business Wire)
Mar-19-25 08:00AM	RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 (Business Wire)
Feb-26-25 08:00AM	RenovoRx Advances Commercialization of RenovoCath with Several New Purchase Orders, Including Customer Reorders (Business Wire)
Feb-13-25 08:00AM	RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery (Business Wire) -11.21%
Feb-11-25 07:00AM	RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock (Business Wire)
Feb-07-25 03:11AM	RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement (GuruFocus.com) -20.55%
Feb-06-25 08:49PM	RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock (Business Wire)
04:05PM	RenovoRx Announces Proposed Public Offering (Business Wire)
Jan-27-25 12:48PM	ASCO GI: RenovoRXs TAMP system reduces side effects in pancreatic cancer (Clinical Trials Arena)
08:00AM	RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 (Business Wire)
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-08-25 08:00AM	RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025 (Business Wire)
Dec-30-24 08:00AM	RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform (Business Wire) +6.92%
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire)
Dec-11-24 08:00AM	RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer (GlobeNewswire)
Dec-10-24 08:00AM	RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET (GlobeNewswire)
Dec-06-24 05:01AM	RenovoRx begins commercialisation of RenovoCath device (Medical Device Network)
Dec-05-24 08:00AM	RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath Delivery System (GlobeNewswire) +15.97%
Nov-20-24 08:45AM	Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire) +7.21%
Nov-14-24 08:00AM	RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Sep-25-24 08:30AM	RenovoRx Increases Production of FDA-Cleared RenovoCath Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians (GlobeNewswire)
Sep-19-24 08:30AM	RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP for Targeted Treatment of Locally Advanced Pancreatic Cancer (GlobeNewswire)
Aug-27-24 08:30AM	RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York (GlobeNewswire)
Aug-14-24 12:13PM	RenovoRx continues drug-device combo Phase III trial in pancreatic cancer (Medical Device Network)
08:30AM	RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire)
Aug-13-24 10:52PM	RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024 (InvestorPlace)
Jul-31-24 08:30AM	RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist (GlobeNewswire) -6.98%
Jul-08-24 08:30AM	RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist (GlobeNewswire) +6.61%
Jun-26-24 08:30AM	University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire)
Jun-10-24 08:30AM	RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships (GlobeNewswire)
May-30-24 08:30AM	RenovoRx CEO Issues Update Letter to Shareholders (Business Wire)
May-21-24 09:00AM	Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRxs TAMP Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery (Business Wire)
May-14-24 09:00AM	RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024 (Business Wire)
May-13-24 09:53AM	RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024 (InvestorPlace)
May-02-24 09:00AM	RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024 (Business Wire)
Apr-18-24 08:30AM	RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement (Business Wire)
Apr-16-24 08:30AM	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Apr-15-24 08:00AM	RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 (Business Wire) -5.74%
Apr-08-24 01:52PM	RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023 (InvestorPlace)
08:30AM	RenovoRx Announces $11.1 Million at Market Private Placement (Business Wire)
Apr-05-24 08:30AM	RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024 (Business Wire)
Mar-12-24 09:00AM	RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024 (Business Wire)
Mar-08-24 04:05PM	RenovoRx Highlights Key Leadership Promotions (Business Wire)
Feb-06-24 08:30AM	RenovoRx CEO Issues Letter to Shareholders (Business Wire)
Jan-29-24 08:30AM	RenovoRx Closes $6.1 Million Private Placement (Business Wire) +15.24%
Dec-21-23 08:30AM	RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer (Business Wire) +19.68%
Dec-19-23 08:30AM	RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting (Business Wire) -8.22%
Dec-13-23 08:31AM	RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform (Business Wire) +25.35%
Nov-16-23 08:35AM	RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D. (Business Wire) -15.82%
Nov-14-23 08:30AM	RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights (Business Wire) -28.34%
Oct-02-23 08:30AM	RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023 (Business Wire) -16.92%
Aug-17-23 08:30AM	RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights (Business Wire) +7.60%
Jul-31-23 08:30AM	RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference (Business Wire)
Jul-20-23 08:00AM	RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform (Business Wire)
Jun-29-23 11:42AM	RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform (News Direct) +9.38%
08:00AM	RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer (Business Wire)

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in 2009 and is headquartered in Mountain View, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Agah Ramtin	Chief Medical Officer	Jan 21 '26	Buy	1.00	10,000	9,975	798,460	Jan 22 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 31 '25	Buy	0.86	9,795	8,424	788,460	Jan 05 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 30 '25	Buy	0.83	205	169	778,665	Jan 02 05:00 PM
Bagai Shaun	Chief Executive Officer	Dec 18 '25	Buy	0.90	5,000	4,506	340,040	Dec 22 07:00 AM
Bagai Shaun	Chief Executive Officer	Dec 17 '25	Buy	0.85	5,000	4,262	335,040	Dec 19 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 16 '25	Buy	0.85	12,000	10,200	778,460	Dec 17 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 05 '25	Buy	0.96	10,000	9,600	766,460	Dec 08 07:00 AM
Agah Ramtin	Chief Medical Officer	Nov 24 '25	Buy	0.80	12,000	9,600	756,460	Nov 24 06:00 PM
Agah Ramtin	Chief Medical Officer	Nov 21 '25	Buy	0.80	10,000	8,000	744,460	Nov 24 06:00 PM
Bagai Shaun	Chief Executive Officer	Aug 22 '25	Buy	0.95	5,000	4,748	325,040	Aug 26 06:10 AM
Bagai Shaun	Chief Executive Officer	Aug 25 '25	Buy	0.91	5,000	4,549	330,040	Aug 26 06:10 AM
Agah Ramtin	Chief Medical Officer	Jun 05 '25	Buy	1.40	21,000	29,400	734,460	Jun 09 06:03 AM
Marton Laurence	Director	May 02 '25	Option Exercise	0.15	20,480	3,072	66,164	May 06 04:10 PM
Agah Ramtin	Chief Medical Officer	Apr 15 '25	Buy	0.90	15,000	13,500	1,113,460	Apr 17 06:10 AM
Bagai Shaun	Chief Executive Officer	Apr 15 '25	Buy	0.91	7,500	6,821	320,040	Apr 16 06:08 AM
Agah Ramtin	Chief Medical Officer	Apr 11 '25	Buy	0.80	20,000	16,000	1,098,460	Apr 14 06:30 AM
Kocak Ron	VP Controller and PAO	Apr 10 '25	Buy	0.79	6,500	5,135	12,595	Apr 10 07:02 PM
Kocak Ron	VP Controller and PAO	Apr 09 '25	Buy	0.80	6,000	4,800	6,095	Apr 10 07:02 PM
Kocak Ron	VP Controller and PAO	Apr 08 '25	Buy	0.80	95	76	95	Apr 10 07:02 PM
Agah Ramtin	Chief Medical Officer	Apr 09 '25	Buy	0.81	30,000	24,399	1,078,460	Apr 10 04:30 PM
Bagai Shaun	Chief Executive Officer	Apr 09 '25	Buy	0.83	10,000	8,300	312,540	Apr 10 06:02 AM
Marton Laurence	Director	Apr 08 '25	Buy	0.85	12,050	10,218	45,684	Apr 09 09:30 PM
Agah Ramtin	Chief Medical Officer	Apr 08 '25	Buy	0.84	26,000	21,840	1,048,460	Apr 09 12:45 PM
Bagai Shaun	Chief Executive Officer	Apr 07 '25	Buy	0.83	10,000	8,300	302,540	Apr 08 11:30 AM

DTIL

Precision Biosciences Inc

RNXT

RenovoRx Inc

Upgrade your FINVIZ experience